Searchable abstracts of presentations at key conferences in endocrinology

ea0015s2biog | Society for Endocrinology Transatlantic Medal Lecture | SFEBES2008

Society for Endocrinology Transatlantic Medal Lecture

Rosenfeld Ron G

Ron G Rosenfeld, Lucile Packard Foundation for Children's Health, Stanford University, Palo Alto, CA., USA. AbstractRon G Rosenfeld, MD, is the Senior Vice-President for Medical Affairs at the Lucile Packard Foundation for Children's Health at Stanford University. He is Professor of Pediatrics at Stanford University, as well as Professor and Chair (emeritus) of Pediatrics and of Cell and Developmental Biology at Oregon...

ea0041gp139 | Paediatric Endocrinology & Development | ECE2016

2nd year efficacy results of once-weekly administration of CTP-modified human growth hormone (MOD-4023): a phase 2 study in children with growth hormone deficiency

Zelinska Nataliya , Skorodok Julia , Malievsky Oleg , Rosenfeld Ron G , Zadik Zvi , Koren Ronit , Amitzi Leanne , Hershkovitz Oren , Hart Gili , Radziuk Klaudziya

Objective: Growth hormone (GH) replacement therapy currently requires daily injections. This may cause poor compliance, inconvenience and distress for patients. CTP-modified hGH (MOD-4023) has been developed for once-weekly administration in growth hormone deficient (GHD) adults and children. The 18 and 24 month efficacy of once-weekly subcutaneous (SC) administration of MOD-4023 was evaluated in a Phase 2 study in children with GH deficiency.Design and ...

ea0041ep845 | Paediatric endocrinology | ECE2016

Safety and tolerability of once-weekly administration of CTP-modified human growth hormone (MOD-4023): phase 2 study in children with growth hormone deficiency

Zelinska Nataliya , Iotova Violeta , Skorodok Julia , Malievsky Oleg , Rosenfeld Ron G. , Zadik Zvi , Koren Ronit , Amitzi Leanne , Hershkovitz Oren , Hart Gili , Radziuk Klaudziya

Objective: Growth hormone (GH) replacement therapy currently requires daily injections. This may cause poor compliance, inconvenience and distress for patients. CTP-modified human GH (MOD-4023) has been developed for once-weekly administration in growth hormone-deficient (GHD) adults and children. In the present Phase 2 study, the safety and tolerability of once-weekly subcutaneous (SC) administration of MOD-4023 were evaluated in GHD children.Design and...